Enter inventor name

Aleksandr M Aliper

This inventor holds 22 USPTO granted patents and 7 published patent applications. Top assignees: Insilico Medicine IP Limited, Deep Longevity Limited, Insilico Medicine, Inc.. Active years: 2019-2025.

USPTO Granted Patents = 22 (Patent Applications = 7)

% Patents Active = 100.0

Average Co-Inventor Count = 3.8

ph-index = 3

Forward Citations = 32(Granted Patents)

Location History:

Ramenskoye, RU (2022)
Moscow, RU (2019 - 2024)

Company Filing History:

20 out of 39

Insilico Medicine IP Limited

patents

1 out of 1

Deep Longevity Limited

patent

1 out of 1

Insilico Medicine, Inc.

patent

Years Active: 2019-2025

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12410156 - Kinase inhibitors (2025-09-09),

2. 12293809 - Workflow for generating compounds with biological activity against a specific biological target (2025-05-06),

3. 12286443 - Bycyclic JAK inhibitors and uses thereof (2025-04-29),

4. 12282851 - Mutual information adversarial autoencoder (2025-04-21),

5. 12227493 - Methods of inhibiting kinases (2025-02-18),

6. 11893498 - Subset conditioning using variational autoencoder with a learnable tensor train induced prior (2024-02-06),

7. 11807622 - TLR 9 inhibitors (2023-11-07),

8. 11795160 - Kinase inhibitors (2023-10-24),

9. 11739078 - Methods of inhibiting kinases (2023-08-29),

10. 11680063 - Entangled conditional adversarial autoencoder for drug discovery (2023-06-20),

11. 11593660 - Subset conditioning using variational autoencoder with a learnable tensor train induced prior (2023-02-28),

12. 11530199 - Analogs for the treatment of disease (2022-12-20),

13. 11530197 - Analogs for the treatment of disease (2022-12-20),

14. 11427591 - Kinase inhibitors (2022-08-30),

15. 11403521 - Mutual information adversarial autoencoder (2022-08-02),

Title: Aleksandr M Aliper: Pioneer in Computational Drug Discovery

Introduction

Aleksandr M Aliper, based in Moscow, Russia, is a remarkable inventor known for his significant contributions to the field of pharmacology and computational drug discovery. With an impressive portfolio of 21 patents, Aliper is at the forefront of innovative methodologies aimed at improving drug design and efficacy.

Latest Patents

Aliper's latest patents reflect cutting-edge research in generating compounds with biological activity targeted at specific biological markers. One such innovation is a comprehensive computer-implemented method that involves receiving biological target input, utilizing a generative model such as the tensorial reinforcement learning (GENTRL) model, generating compound structures, prioritizing them based on predetermined criteria, and ultimately processing these structures to uncover hit compounds. Additionally, he has developed bycyclic JAK inhibitors that hold promise for treating various immune and inflammatory disorders, as well as cancer.

Career Highlights

Throughout his career, Aliper has collaborated with notable institutions, including Insilico Medicine IP Limited and Insilico Medicine, Inc. His background in advanced computational techniques has enabled him to pioneer innovative approaches in biopharmaceutical development. The success of his patents illustrates a profound understanding of the intersection between computer science and biology.

Collaborations

Aleksandr's collaborative efforts have led him to work alongside prominent figures in the industry, including Aleksandrs Zavoronkovs and Vladimir Aladinskiy. Together, they have pushed the boundaries of drug discovery through a combination of expertise in artificial intelligence, pharmacology, and medicinal chemistry.

Conclusion

Aleksandr M Aliper stands as a leading inventor in the domain of drug discovery and computational methods. His 21 patents not only signify his innovative spirit but also contribute significantly to addressing some of the most pressing health challenges of our time.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]